Graft-versus-host disease: New directions for a persistent problem

Blood

Volumn 84, Issue 7, 1994, Pages 2061-2067

  Vogelsang, Georgia B ^a   Hess, Allan D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; CYTOKINE; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR ALPHA;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN RECOGNITION; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION; WHOLE BODY RADIATION;

EID: 0028111081     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v84.7.2061.2061     Document Type: Review

References (61)

1. Barnes DWH, Loutit JF: Spleen protection: The cellular hypothesis, in Bacq ZM (ed): Radiobiology Symposium Liegè. London, UK, Butterworths, 1955, p 134
2. Trentin JJ: Mortality and skin transplantability in irradiated mice receiving isologous or heterologous bone marrow. Proc Soc Exp Biol Med 92:688, 1956
3. Billingham RE: The biology of graft-versus-host reactions. Harvey Lect 62:21, 1967
4. Gluckman E, Devergie A, Sohier J, Sauret SH: Graft versus host disease in recipients of syngeneic bone marrow. Lancet i:253, 1980
5. Thien SW, Goldman JM, Galton DG: Acute "graft versus host disease" after autologous grafting for chronic granulocytic leukemia in transplantation. Ann Intern Med 94:210, 1981
6. Hood AF, Vogelsang GB, Black C, Farmer ER, Santos GW: Acute graft versus host disease: Development following autologous and syngeneic bone marrow transplantation. Arch Dermatol 123:745, 1987
7. Glazier A, Tutschka PJ, Farmer ER, Santos GW: Graft-versus-host disease in cyclosporin A treated rats after syngeneic and autologous bone marrow reconstitution. J Exp Med 158:1, 1983
8. Glazier A, Tutschka PJ, Farmer ER: Studies on the immunobiology of syngeneic and autologous graft-versus-host disease in cyclosporine treated rats. Trans Proc 15:3035, 1983
9. Hess AD, Horwitz L, Beschorner WE, Santos GW: Development of graft-versus-host disease-like syndrome in cyclosporinetreated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T-lymphocytes with apparent polyclonal anti-la specificity, including autoreactivity. J Exp Med 161:718, 1985
10. Hess AD, Horwitz LR, Laulis MK: Cyclosporine induced syngeneic graft-versus-host disease: Recognition of self MHC class II antigens in vivo. Transplant Proc 25:1218, 1993
11. Cheney RT, Sprent J: Capacity of cyclosporine to induce autograft-versus-host disease and impair intrathymic T-cell differentiation Transplant Proc 17:528, 1985
12. Beschorner WE, Shinn CA, Hess AD, Suresch DL, Santos GW: Immune related injury to endothelium associated with acute graft-vs-host disease in the rat. Trans Proc 21:3025, 1989
13. Shinozawa T, Beschorner WE, Hess AD: Prolonged administration of cyclosporine and the thymus: Irreversible immunopathologic changes associated with autologous pseudo-graft-vs-host disease. Transplant 50:106, 1990
14. Beschorner WE, Ren H, Phillip J, Pulido HB, Hiaban RH, Hess AD: Recovery of thymic microenvironment after cyclosporine prevents syngeneic graft-vs-host disease. Transplant 52:668, 1991
15. Ryffel B, Deyssenroth H, Borel JH: Cyclosporin A: effects on the mouse thymus. Agents Actions 11:373, 1981
16. Beschorner WE, Nammorim JF, Hess AD, Shinn CA, Santos GW: Cyclosporine A and the thymus: Immunopathology. Am J Pathol 126:487, 1987
17. Fabien NH, Auger C, Moreira A, Monier JC: Effects of cyclosporin A on mouse thymus: Immunochemical and ultrastructural studies. Thymus 20:153, 1992
18. Beschorner WE, Suresch DL, Shinozawa T. Santos GW. Hess AD: Influence of irradiation and age on the CsA induced thymic immunopathology. Transplant Proc 20:1072, 1988
19. Beschorner WE, Ren H, Phillip J, Pulido HB, Hruban RH, Hess AD: Recovery of thymic microenvironment after cyclosporine prevents syngeneic graft-vs-host disease. Transplant 52:668, 1991
20. Fischer AC, Laulis MK, Horwitz L, Hess AD: Effect of cyclosporine on T lymphocyte development: Relationship to syngeneic graft-versus-host disease. Transplant 51:252, 1991
21. Zhang H, Horwitz LR, Fischer AC, Colombani PM, Hess AD: Adoptive transfer of cyclosporine-induced MHC class II autoreactive cells prolong heart allograft survival. Transplant Sci 3:17, 1993
22. Hess AD, Vogelsang GB, Heyd J, Beschorner WE: Cyclosporine induced syngeneic graft-vs-host disease, assessment of T-cell differentiation. Transplant Proc 19:2683, 1987
23. Shinozawa T, Beschorner WE, Hess AD: Prolonged administration of cyclosporine irreversible immunopathologic changes associated with autologous pseudo-graft-vs-host disease. Transplant 50:106, 1990
24. Herber-Katz E, Acha-Orbea H: The v-region hypothesis: Evidence from autoimmune encephalomyelitis. Immunol Today 10:64, 1989
25. Severino ME, Laulis MK, Horwitz LR, Hess AD: Cyclosporine preferentially inhibits clonal deletion of CDS positive T-cells with an MHC class II restricted autoreactive T-cell receptor. Transplant 25:520, 1993
26. Hess AD, Fischer AC, Ruvolo PP, Fuchs EJ: A failure of central and peripheral tolerance mechanisms, in Ildstad S (ed): Chimerism and Tolerance. Austin, TX, Landes, 1994 (in press)
27. Hess AD, Vogelsang GB, Silankis M, Friedman KA, Beschorner WE, Santos GW: Syngeneic graft-vs-host disease (GVHD) after allogeneic bone marrow transplantation and cyclosporine treatment. Transplant Proc 20:487, 1988
28. Severino ME, Laulis MK. Horwitz LR, Hess AD: Cyclosporine preferentially inhibits clonal deletion of CD8 positive T cells with an MHC class II restricted autoreactive T cell receptor. Transplant Proc 25:520, 1993
29. Parkman R: Clonal analysis of graft-vs-host disease, in Burkoff, Deeg HJ, Ferrara J (eds): Graft-vs-Host Disease, New York, NY, Dekker, 1990, p 51
30. Geller R, Esa A, Benhomer W, Frondoza C, Santos GW, Hess AD: Successful in vitro graft-versus-tumor effect against an la-bearing tumor using cyclosporine induced syngeneic graft-versus-host disease in the rat. Blood 74:1165, 1989
31. Kennedy MJ, Vogelsang GB, Beveridge RA, Farmer ER, Altomonte V, Huelskamp AM, Davidson NE: Phase I trial of intravenous cyclosporine A to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 11:478, 1993
32. Jones RJ, Vogelsang GB, Hess AD, Farmer ER, Mann RB, Geller RB, Piantadosi S, Santos GW: Induction of graft versus host disease after autologous bone marrow transplantation. Lancet i:754, 1989
33. Kennedy MJ, Vogelsang GB, Jones RJ, Farmer ER, Hess AD, Altomonte V, Huelskamp AM, Davidson NE: Phase I trial of interferon-gamma to potentiate cyclosporine A induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 12:249, 1994
34. Yeager AM, Vogelsang GB, Jones RJ, Farmer ER, Hess AD, Santos GW: Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation for acute myloid leukemia. Leuk Lymphoma 11:215, 1993
35. Jones RJ, Vogelsang GB, Ambinder RF, Santos GW. Hess AD: Autologous marrow transplant with cyclosporine induced autologous graft-versus-host disease for relapsed aggressive non-Hodgkin's lymphoma. Blood 78:287a, 1991 (abstr, suppl)
36. Guillen FJ, Ferrara J, Hancock WW, Messadi D, Fonferko E, Burakoff SJ, Murphy GF: Acute cutaneous graft-versus-host disease to minor histo-compatibility antigens in a murine model: evidence that large granular lymphocytes are effector cells in the immune response. Lab Invest 55:35, 1986
37. Ferrara J, Burakoff S: The pathophysiology of acute graft-versus-host disease in a murine bone marrow transplant model, in Burakoff S, Deeg HJ, Ferrara J, Atkinson K (eds): Graft-versus-Host Disease: Immunology, Pathophysiology and Treatment. New York, NY, Dekker, 1990, p 9
38. Vossen JM, Heidt PJ: Gnotobiotic measure for the prevention of acute graft-versus-host disease, in Burakoff S, Deeg HJ, Ferrara J, Atkinson K (eds): Graft-versus-Host Disease: Immunology, Pathophysiology and Treatment. New York, NY, Dekker, 1990, p 403
39. Sullivan KM, Kopecky KS, Jocom J, Fisher L, Buckner CD, Meyers J, Counts G, Bowden R, Petersen F, Witherspoon R, Budninger M, Schwartz R, Appelbaum F, Cift R, Hansen J, Sanders J, Thomas ED, Storb R: Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323:705, 1990
40. Johnson BD, Drobyski WR, Truitt RL: Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-vs-host disease. Bone Marrow Transplant 11:329, 1993
41. Tutschka PJ, Beschorner WE, Allison AC, Burns WH, Santos GW: Use of cyclosporine A in allogeneic bone marrow transplant in the rat. Nature 280:148, 1979
42. Storb R, Deeg HJ, Whithead J, Appelbaum FR, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sandors J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729, 1986
43. Santos GW, Tutschka PJ, Brookmyer R, Beschorner WF, Bias WB, Braine HG, Burns WH, Famer ER, Hess AD, Kaizer H, Mellitis D, Sensenbrenner L, Stuart R, Yeager AM: Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease. A randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1:21, 1987
44. Chao NS, Schmidt G, Niland J, Amylon M, Dagio A, Long G, Nademanee A, Negrin R, O'Donnell M, Parker P, Smith E, Snyder D, Stein A, Wong R, Blume K, Forman S: Cyclosporine, methotrexate and prednisone compared with cyclosporine and prednisone for prophylaxis for acute graft-versus-host disease. N Engl J Med 329:1225, 1993
45. Theobald M, Nierle T, Bunjes D, Arnold R, Heimpel H: Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med 327:1613, 1992
46. Schwarer A, Jiang Y, Brookes P, Barren AJ, Batchelor JR, Goldman JM, Lechler RI: Frequency of antirecipient alloreactive helper T-cell precursors in donor blood in graft-vs-host disease after LA-identical siblings bone marrow transplantation. Lancet i:203, 1993
47. Nierle T, Bunjes D, Arnold R, Heimpel H, Theobald M: Quantitative assessment of post transplant host-specific interleukin-2-secreting T-helper cell precursors in patients with and without graft-versus-host after allogeneic HLA-identical sibling bone marrow transplants. Blood 81:841, 1993
48. Herve P, Wijdenes J, Bergerat JP, Bordigioni P, Milpied N, Cahn JY, Clement C, Beliard R, Morel-Fourrier B, Racadot E: Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibodies (B-B10). Blood 75:1017, 1990
49. Anasetti C, Hansen JA, Waldmann T, Diagi MH, Mould D. Satoh H, Appelbaum FR, Deeg HJ, Doney K, Martin PS, Nack R, Sullivan KM, Witherspoon R, Storb R: Treatment of acute graft-versus-host disease with a humanized monoclonal antibody specific for the interleukin-2 receptor. Blood 80:1484, 1992
50. Piguet PF: Tumor necrosis factor and graft-versus-host disease, in Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds): Graft-Versus-Host Disease: Immunology, Pathophysiology, and Treatment. New York, NY, Dekker, Inc, 1990, p 255
51. Holler E, Kolb HJ, Hintermeier-Knabe R, Mittermuller J, Thierfelder S, Kaul M, Wilmanns W: Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc 25:1234, 1993
52. Herve P, Flesch M, Tiberghien P, Wijdenes J, Racadot E, Bordigoni P, Plouvier E, Stephan JL, Bourdeau H, Holler E: Phase I-II trial of monoclonal anti-tumor necrosis alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 79:3362, 1992
53. Bianco JA, Appelbaum FR, Nemunaitis J, Almgren J, Andrews F, Kettner P, Shields A, Singer JW: Phase I-II trial of pentoxifylline for prevention of transplant-related toxicities following bone marrow transplantation. Blood 78:1205, 1991
54. Clift RA, Bianco JA, Appelbaum FR, Buckner CD, Singer JW, Bakke L, Bensinger W, Bowden R, McDonald G, Schubert M, Shields A, Slattery W, Storb R, Fisher L, Mori M, Thomas ED, Hansen JA: A randomized controlled trial of pentoxicylline for the prevention of regimen-related toxicities in patients undergoing allogeneic transplantation. Blood 82:2025, 1993
55. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173:699, 1991
56. Abhyankar S, Gilliand D, Ferar A: Interleukin 1 is a critical effector molecule during cytokine dysregulation and graft-vs-host disease to minor histocompatibility antigens. Transplantation 56:1518, 1994
57. Niederwieser D, Herold M, Woloszczuk W, Aulitzky W, Meister B, Tilg H, Gastl G, Bowden R, Huber C: Endogenous INFgamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation 50:620, 1990
58. Allen RD, Staley TA, Sidman CL: Differential cytokine expression in acute and chronic murine graft-versus-host disease. Eur J Immunol 23:333, 1993
59. Nestel FP, Price KS, Seemayer TA, Lapp WS: Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 175:405, 1992
60. Fowler DH, Kurasawa K, Husebekk A, Cohen P, Gress R: Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. J Immunol 152:1004,1994
61. + T cell activity. J Immunol 150:197, 1993